Quarterly report pursuant to Section 13 or 15(d)

License Agreements

v2.4.0.6
License Agreements
9 Months Ended
Aug. 31, 2012
License Agreements [Abstract]  
License Agreements

Note 5 – License Agreements

The Company has entered into license agreements with certain investors in various international markets in an attempt to capitalize on the Company’s technology. The investors typically pay a licensing fee to receive Company marketing programs and/or the Company’s technology and expertise in a selected area. The license agreement may also give the investor the right to sell sub-license agreements. As part of the accounting for the up-front license revenue, revenue from the up-front license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed based on the terms of the agreement.

The Company enters into two types of license agreements and in both types the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company’s facility in Oldsmar, Florida.

Technology Agreements

The Company has entered into definitive License and Royalty Agreements with Cryo-Cell de Mexico (“Mexico”) and Asia Cryo-Cell Private Limited to establish and market its umbilical cord blood program in Mexico and India, respectively.

 

The Company has entered into definitive License and Royalty Agreements with Asia Cryo-Cell Private Limited and S-Evans Bio-Sciences, Inc. to establish and market its menstrual stem cell program in India and China, respectively.

On August 19, 2011, the Company received notification from Mexico that it was terminating the license agreement effective immediately due to an alleged breach of the license agreement. On October 17, 2011, the Company and Mexico entered into an amendment to the license agreement whereby the termination was revoked and Mexico began to pay the Company $1,863,000 in 37 monthly installments of $50,000 beginning on October 17, 2011 with a final payment of $13,000. Mexico will have no other continuing obligations to the Company for royalties or other license payments and the agreement will be effectively terminated once the entire $1,863,000 has been received. Mexico also has the option to pay off the amount early with no penalties. The amendment is expected to result in a reduction of licensee income in future periods once the $1,863,000 is paid in full.

As of August 31, 2012 and November 30, 2011, the Company recorded a receivable from Mexico of $1,252,947 and $1,656,476, respectively, and deferred revenue of $1,239,144 and $1,633,910, respectively, in the accompanying consolidated balance sheets. Accounts receivable is calculated using the present value of all of the monthly installments using a discount rate that reflects both the risk-free rate at the inception of the contract and the contract period. In accordance with the agreement, the Company received nine installments of $50,000 during the nine months ended August 31, 2012, which is reflected in the consolidated statement of operations as of August 31, 2012 as licensee and other income. The installment amounts that are to be received and recognized within the next twelve months have been classified as short-term as Accounts Receivable in the accompanying consolidated balance sheets.

Marketing Agreements

The Company has entered into definitive license agreements giving third parties the right to market both the Company’s umbilical cord blood and menstrual stem cell programs in Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Pakistan, Peru, and Venezuela. In October 2012, the Company sent notice of termination to the Company’s Venezuelan affiliate for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Venezuela. The Company is in the process of discussing a new agreement.

Processing and storage revenues from specimens originating in foreign territories that store at the Company’s facility in Oldsmar, Florida totaled approximately $392,000 and $314,000 for the three months ended August 31, 2012 and 2011 and are reflected in processing and storage fees in the accompanying consolidated statements of operations. Processing and storage revenues from specimens originating in foreign territories that store at the Company’s facility in Oldsmar, Florida totaled approximately $1,185,000 and $992,000 for the nine months ended August 31, 2012 and 2011 and are reflected in processing and storage fees in the accompanying consolidated statements of operations.

The following table details the initial license fees for the technology and marketing agreements and processing and storage royalties earned for the technology agreements for the three months ended August 31, 2012 and 2011 and the nine months ended August 31, 2012 and 2011. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of operations.

 

 

                                                 
    Three Months Ended August 31, 2012     Nine Months Ended August 31, 2012  
    License
Fee
    Process
and
Storage
Royalties
    Total     License
Fee
    Process
and
Storage
Royalties
    Total  

India

    —         169,412       169,412       —         508,235       508,235  

Mexico

    —         156,969       156,969       —         464,021       464,021  

Costa Rica

    25,000       —         25,000       25,000       —         25,000  

Nicaragua

    5,000       —         5,000       20,000       —         20,000  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $ 30,000     $ 326,381     $ 356,381     $ 45,000     $ 972,256     $ 1,017,256  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     
    Three Months Ended August 31, 2011     Nine Months Ended August 31, 2011  
    License
Fee
    Process
and
Storage
Royalties
    Total     License
Fee
    Process
and
Storage
Royalties
    Total  

China

                                  $ 50,000     $ 50,000  

India

  $ —       $ 141,177     $ 141,177     $ —         423,530       423,530  

Mexico

    —         177,747       177,747       —         453,015       453,015  

Costa Rica

    15,983               15,983       15,983               15,983  

Germany (1)

                            9,769               9,769  

Nicaragua

            —                 10,000       —         10,000  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $ 15,983     $ 318,924     $ 334,907     $ 35,752     $ 926,545     $ 962,297  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(1) Innovative Medical Solutions SRL (“Germany”) advised the Company that it intends to terminate the umbilical cord blood and menstrual stem cell license agreements. Per the terms of the agreements, Germany owed the Company $50,000 on October 1, 2010. The Company has not recorded any revenue associated with the two agreements in the Company’s consolidated statements of operations for the three and nine months ended August 31, 2012. The Company recorded a payment of $0 and $9,769 as revenue in the Company’s consolidated statements of operations for the three and nine months ended August 31, 2011.